Immunotherapy spinout Annexon Biosciences collected funding from Novartis Venture Fund in a series C round that brought its total funding to $154m.
Annexon Biosciences, a US-based immunotherapy developer spun out from Stanford University, closed a $75m series C round on Wednesday backed by Novartis Venture Fund, the corporate venturing vehicle for pharmaceutical firm Novartis. Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, led the round, which included Surveyor Capital, Adage Capital Partners, New Enterprise…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
